Eliza Hawkes

Dr

20072019
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2007 2019

Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-cell lymphoma: not yet the standard of care

Casan, J. ML., Barraclough, A., Shortt, J. & Hawkes, E. A., 1 Mar 2019, In : The Lancet Haematology. 6, 3, p. e119 1 p.

Research output: Contribution to journalLetterOtherpeer-review

Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab era

Tamjid, B., Mckendrick, J., Schwarer, A., Doig, R., James, P., Hosking, P. & Hawkes, E. A., 1 Jun 2017, In : Asia-Pacific Journal of Clinical Oncology. 13, 3, p. 226-233 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Is upfront escalated BEACOPP for advanced Hodgkin lymphoma becoming a distant memory?

Hawkes, E. A., Chong, G. & Grigg, A., 20 Jan 2017, In : Journal of Clinical Oncology. 35, 3, p. 371-372 2 p.

Research output: Contribution to journalLetterOtherpeer-review

Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013

Gleeson, M., Hawkes, E. A., Peckitt, C., Wotherspoon, A., Attygalle, A., Sharma, B., Du, Y., Ethell, M., Potter, M., Dearden, C., Horwich, A., Chau, I. & Cunningham, D., 3 Aug 2017, In : Leukemia and Lymphoma. 58, 8, p. 1805-1813 9 p.

Research output: Contribution to journalArticleResearchpeer-review